Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 323 participants.
Also called NCT01850615
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 323 participants
- Sponsor
- Registry
-
NCT01850615 -
2012-005583-10 -
CTRI/2014/01/004289
-
- Main results
- Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18-week, open-label, phase 3 trial (onset 3)
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, India, Mexico, Romania, Slovenia
- Registry status
- Completed
Technical summary
Registry record NCT01850615. Randomized; no masking; primary purpose treatment. Start 2013-09-23 (actual); primary completion 2014-11-17 (actual). Results posted on 2018-01-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes
- Acronym
- onset® 3
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Faster-acting insulin aspart
- Intervention (Drug)
- basal insulin
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01850615- Content hash
1f74faa0008f19637683aea58a7f2317f704b8b115d1fb6e2f1b6daa2fc33930